HYPOXIA-RESPONSIVE MICRORNA-101 PROMOTES ANGIOGENESIS VIA HEME OXYGENASE-1/VEGF AXIS BY TARGETING CULLIN 3

摘要

The present invention uses the angiogenesis promotion effects of microRNA-101 (miR-101) and, specifically, relates to a pharmaceutical composition for angiogenesis or to a pharmaceutical composition for preventing or treating ischemic diseases, which inhibits cullin3 by containing miR-101 or an agonist thereof. If the pharmaceutical composition of the present invention is used, angiogenesis can be effectively promoted in areas where angiogenesis is needed, and ischemic diseases can be effectively prevented and treated. In addition, when a screening method of the present invention is used, a novel angiogenesis accelerator or a medicine for preventing or treating ischemic diseases can be efficiently developed. This study is carried out with the support of the National Research Foundation of Korea funded by the government [Ministry of Education] in 2011 [No. NRF-2011-0028790].